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ARTICLE
Neural network analysis of sleep stages enables
efﬁcient diagnosis of narcolepsy
Jens B. Stephansen1,2, Alexander N. Olesen1,2,3, Mads Olsen1,2,3, Aditya Ambati 1, Eileen B. Leary 1,
Hyatt E. Moore1, Oscar Carrillo1, Ling Lin1, Fang Han4, Han Yan4, Yun L. Sun4, Yves Dauvilliers5,6,
Sabine Scholz5,6, Lucie Barateau5,6, Birgit Hogl7, Ambra Stefani7, Seung Chul Hong8, Tae Won Kim8,
Fabio Pizza9,10, Giuseppe Plazzi9,10, Stefano Vandi9,10, Elena Antelmi9,10, Dimitri Perrin11, Samuel T. Kuna12,
Paula K. Schweitzer13, Clete Kushida1, Paul E. Peppard14, Helge B.D. Sorensen2, Poul Jennum3 &
Emmanuel Mignot1
Analysis of sleep for the diagnosis of sleep disorders such as Type-1 Narcolepsy (T1N)
currently requires visual inspection of polysomnography records by trained scoring techni-
cians. Here, we used neural networks in approximately 3,000 normal and abnormal sleep
recordings to automate sleep stage scoring, producing a hypnodensity graph—a probability
distribution conveying more information than classical hypnograms. Accuracy of sleep stage
scoring was validated in 70 subjects assessed by six scorers. The best model performed
better than any individual scorer (87% versus consensus). It also reliably scores sleep down
to 5 s instead of 30 s scoring epochs. A T1N marker based on unusual sleep stage overlaps
achieved a speciﬁcity of 96% and a sensitivity of 91%, validated in independent datasets.
Addition of HLA-DQB1*06:02 typing increased speciﬁcity to 99%. Our method can reduce
time spent in sleep clinics and automates T1N diagnosis. It also opens the possibility of
diagnosing T1N using home sleep studies.
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S leep disorders and sleep dysregulation impact over 100million Americans, contributing to medical consequencessuch as cardiovascular (arrhythmia, hypertension, stroke),
metabolic (diabetes, obesity) and psychiatric disorders (depres-
sion, irritability, addictive behaviors). Sleep deprivation impairs
performance, judgment and mood, and is a major preventable
contributor to accidents1. There are ~90 different sleep disorders
including insomnia (20% of population), obstructive and central
sleep apnea (10%), restless legs syndrome (4%), rapid eye
movement (REM) sleep behavior disorder (RBD) and hyper-
somnia syndromes such as type 1 narcolepsy (T1N)2.
Among these pathologies, T1N is unique as a disorder with a
known, discrete pathophysiology—a destruction of hypocretin
neurons in the hypothalamus likely of autoimmune origin3. This
is reﬂected in the cerebrospinal ﬂuid (CSF) concentrations of the
hypocretin-1 (orexin-A) neuropeptide, where a concentration
below 110 pg/ml is considered indicative of narcolepsy2. Typically
beginning in childhood or adolescence, narcolepsy affects
approximately 0.03% of the US, European, Korean and Chinese
populations4. Unique to narcolepsy is the extremely strong (97%
versus 25%) association with a genetic marker, HLA-
DQB1*06:025, and a well-characterized set of sleep disturbances
that include short sleep latency, rapid transitions into REM sleep
and poor nocturnal sleep consolidation. The pathology also
includes episodes of “sleep/wake dissociation” where the patient is
half awake and half in REM sleep, for example, experiencing REM
sleep muscle paralysis while awake (sleep paralysis, cataplexy) or
dreaming while awake (hypnagogic hallucinations).
Sleep disorders are generally assessed at sleep clinics by per-
forming sleep analysis using nocturnal polysomnography (PSG),
a recording comprised of multiple digital signals which include
electroencephalography (EEG), electrooculography (EOG), chin
and leg electromyography (EMG), electrocardiography, breathing
effort, oxygen saturation and airﬂow6. When sleep is analyzed in
PSGs, it is divided into discrete stages: wake, non-REM (NREM)
sleep stage 1 (N1), 2 (N2) and 3 (N3), and REM. Each stage is
characterized by different criteria, as deﬁned by consensus rules
published in the American Academy of Sleep Medicine (AASM)
Scoring Manual6,7. N1 (sleep onset) is characterized by slowing of
the EEG, disappearance of occipital alpha waves, decreased EMG
and slow rolling eye movements, while N2 is associated with
spindles and K-complexes. N3 is characterized by a dominance of
slow, high amplitude waves (>20%), while REM sleep is asso-
ciated with low voltage, desynchronized EEG with occasional saw
tooth waves, low muscle tone and REMs. PSG analysis is typically
done by certiﬁed technicians who, through visual inspection on a
standardized screen, assign a sleep stage to each 30 s segment of
the full recording. Although there is progression from N1 to N3
then to REM during the night, a process that repeats approxi-
mately every 90 min (the sleep cycle), each stage is associated with
physiological changes that can be meaningful to the assessment of
sleep disorders such as obstructive sleep apnea. For example, the
abnormal breathing events that occur with obstructive sleep
apnea (OSA) are generally less severe in N3 versus N2 because of
central control of breathing changes, and they are more severe in
REM sleep, due to upper airway muscle weakness8. The differ-
entiation of sleep stages is also particularly important for the
diagnosis of narcolepsy, a condition currently assessed by a PSG
followed by a multiple sleep latency test (MSLT), a test where
patients are asked to nap 4–5 times for 20 min every 2 h during
the daytime and sleep latency and the presence of REM sleep is
noted9. A mean sleep latency (MSL) less than 8 min (indicative of
sleepiness) and the presence of at least 2 sleep onset REM periods
(SOREMPs, REM latency ≤15 min following sleep onset in naps)
during the MSLT or 1 SOREM plus a REM latency ≤15 min
during nocturnal PSG is diagnostic for narcolepsy. In a recent
large study of the MSLT10, speciﬁcity and sensitivity for type 1
narcoleptics were, respectively, 98.6% and 92.9% in comparing
516 T1N versus 516 controls and 71.2% and 93.4% in comparing
122 T1N cases versus 132 other hypersomnia cases (high pretest
probability cohort). Similar sensitivity (75–90%) and speciﬁcity
(90–98%) have been reported by others in large samples of
hypersomnia cases versus T1N11–15.
Manual inspection of sleep recordings has many problems. It is
time consuming, expensive, inconsistent, subjective and must
generally be done ofﬂine. In one study, Rosenberg and Van
Hout16 found inter-scorer reliability for sleep stage scoring to be
82.6% on average, a result consistently found by others17–20. N1
and N3 in particular have agreements as low as 63 and 67%,
placing constraints on their usefulness16. In this study, we
explored whether deep learning, a speciﬁc subtype of machine
learning, could produce a fast, inexpensive, objective, and
reproducible alternative to manual sleep stage scoring. In recent
years, similar complex problems such as labeling images,
understanding speech and translating language have seen
advancement to the point of outperforming humans21–23. Several
high-proﬁle papers have also documented the efﬁcacy of deep
learning algorithms in the healthcare sector, especially in the
ﬁelds of diabetic retinopathy24,25, digital pathology26,27 and
radiology28,29. This technology refers to complex neural network
models with a very large number (on a magnitude of millions)
of parameters and processing layers. For a thorough review
of the underlying theory behind deep learning including
common model paradigms, we refer to the review article by
LeCun et al.30.
In this implementation of deep learning, we introduce the
hypnodensity graph—a hypnogram that does not enforce a
single sleep stage label, but rather a membership function to each
of the sleep stages, allowing more information about sleep trends
to be conveyed, something that is only possible in non-human
scoring. Using this concept, we next applied deep learning-
derived hypnodensity features to the diagnosis of T1N, showing
that an analysis of a single PSG night can perform as well as the
PSG-MSLT gold standard, a 24 h long procedure.
Results
Inter-scorer reliability cohort. Supplementary Table 1 reports on
the description of the various cohorts included in this study, and
how they were utilized (see Datasets section in Methods). These
originate from seven different countries. We assessed inter-scorer
reliability using the Inter-scorer Reliability Cohort (IS-RC)31, a
cohort of 70 PSGs scored by 6 scorers across three locations in the
United States31. Table 1 displays individual scorer performance as
well as the averaged performance across scorers, with top and
bottom of table showing accuracies and Cohen’s kappas,
respectively. The results are shown for each individual scorer
when compared to the consensus of all scorers (biased) and
compared to the consensus of the remaining scorers (unbiased).
In the event of no majority vote for an epoch, the epoch was
counted equally in all classes in which there was disagreement.
Also shown in Table 1 is the model performance on the same
consensus scorings as each individual scorer along with the t-
statistic and associated p value for each paired t-test between the
model performance and individual scorer performance. At a
signiﬁcance level of 5%, the model performs statistically better
than any individual scorer both in terms of accuracy and Cohen’s
kappa.
Supplementary Table 2 displays the confusion matrix for every
epoch of every scorer of the inter-scorer reliability data, both
unadjusted (top) and adjusted (bottom). As in Rosenberg and
Van Hout16, the biggest discrepancies occur between N1 and
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Wake, N1 and N2, and N2 and N3, with some errors also
occurring between N1 and REM, and N2 and REM.
For future analyses of the IS-RC in combination with other
cohorts that have been scored only by one scorer, a ﬁnal
hypnogram consensus was built for this cohort based on the
majority vote weighted by the degree of consensus from each
voter, expressed as its Cohen’s κ, κ ¼ 1 1po1pe , where pe is the
baseline accuracy and po is the scorer accuracy, such that
y ¼ argmax
P6
i¼1 byi  κiP6
i¼6 κi
: ð1Þ
In this implementation, scorers with a higher consensus with
the group are considered more reliable and have their assessments
weighted heavier than the rest. This also avoided split decisions
on end-results.
Optimizing machine learning performance for sleep staging.
We next explored how various machine learning algorithms (see
Methods) performed depending on cohort, memory (i.e., feed
forward (FF) versus long short-term memory networks (LSTM)),
signal segment length (short segments of 5 s (SS) versus long
segments of 15 s (LS)), complexity (i.e., low (SH) vs. high (LH)),
encoding (i.e., octave versus cross-correlation (CC) encoding, and
realization type (repeated training sessions). The performance of
these machine learning algorithms was compared with the six-
scorer consensus in the IS-RC and with single scorer data in 3
other cohorts, the Stanford Sleep Cohort (SSC)10,32, the Wis-
consin Sleep Cohort (WSC)32,33 and the Korean Hypersomnia
Cohort (KHC)10,34 (see Datasets section in Methods for
description of each cohort).
Model accuracy varies across datasets, reﬂecting the fact scorer
performance may be different across sites, and because unusual
subjects such as those with speciﬁc pathologies can be more
difﬁcult to score—a problem affecting both human and machine
scoring. In this study, the worst performance was seen in the
KHC and SSC with narcolepsy, and the best performance was
achieved on IS-RC data (Supplementary Figure 1a, Table 2,
Supplementary Table 7). The SSC+KHC cohorts mainly contain
patients with more fragmented sleeping patterns, which would
explain a reduced performance. The IS-RC has the most accurate
label, minimizing the effects of erroneous scoring, which
therefore leads to an increased performance. Incorporating large
ensembles of different models increased mean performance
slightly (Table 2).
The two most important factors that increased prediction
accuracy were encoding and memory, while segment length,
complexity and number of realizations were less important
(Supplementary Figure 1). The effect of encoding was less
prominent in the IS-RC. Prominent factor interactions include
(Supplementary Figure 2): (i) CC encoding models improve with
higher complexity, whereas octave encoding models worsen; (ii)
increasing segment length positively affects models with low
complexity, but does not affect models with a high complexity;
and (iii) adding memory improves models with an octave
encoding more than models with a CC encoding. Because the IS-
RC data are considered the most reliable, we decided to use these
data as benchmark for model comparison. This standard
improved as more scorers were added, and the model
performance increased. (Fig. 1a). The different model conﬁgura-
tions described in this section do not represent exhaustive
conﬁguration search, and future work experiments might result in
improved results.
Figure 2a displays typical scoring outputs (bottom panels)
obtained with a single sleep study of the IS-RC cohort in
comparison to 6 scorer consensus (top panel). The model results
are displayed as hypnodensity graphs, representing not only
discrete sleep stage outputs, but also the probability of occurrence
of each sleep state for each epoch (see deﬁnition in Data labels,
scoring and fuzzy logic section). As can be seen, all models
performed well, and segments of the sleep study with the lowest
scorer consensus (top) are paralleled by similar sleep stage
probability uncertainty, with performance closest to scoring
consensus achieved by an ensemble model described below
(second to top).
Final implementation of automatic sleep scoring algorithm.
Because of model noise, potential inaccuracies and the desire to
quantify uncertainty, the ﬁnal implementation of our sleep
scoring algorithm is an ensemble of different CC models with
small variations in model parameters, such as the number of
feature-maps and hidden nodes. This was achieved by randomly
varying the parameters between 50 and 150% of the original
values using the CC/SH/LS/LSTM as a template (this model
achieved similar performance to the CC/LH/LS/LSTM while
requiring signiﬁcantly less computational power).
All models make errors, but as these errors occur indepen-
dently of each other, the risk of not detecting and correcting
errors falls with increasing model numbers. For this reason,
16 such models were trained, and at each analyzed segment both
mean and variance of model estimates were calculated. As
expected, the relative model variance (standardized to the average
variance in a correct wakefulness prediction) is generally lower in
correct predictions (Supplementary Table 3) and this can be used
to inform users about uncertain/incorrect estimates. To demon-
strate the effectiveness of this ﬁnal implementation, the average of
the models is shown alongside the distribution of 5234 ±
14 scorers on 150 epochs, a dataset provided by the AASM
(AASM inter-scorer reliability (ISR) dataset, (see Datasets section
Table 1 Individual and overall scorer performance, expressed as accuracy and Cohen’s kappa
Overall Scorer 1 Scorer 2 Scorer 3 Scorer 4 Scorer 5 Scorer 6
Accuracy (%), biased 81.3 ± 3.0 82.4 ± 6.1 84.6 ± 5.5 74.1 ± 7.9 85.4 ± 5.7 83.1 ± 9.4 78.3 ± 8.9
Accuracy (%), unbiased 76.0 ± 3.2 77.3 ± 6.3 79.1 ± 6.3 69.0 ± 8.0 79.7 ± 6.5 77.8 ± 9.6 72.9 ± 9.2
Model accuracy (%) on
concensus
— 85.1 ± 4.9 83.8 ± 5.0 86.5 ± 4.3 84.3 ± 4.7 85.6 ± 4.7 87.0 ± 4.5
T-stat (p value) — 9.5 (3.8 × 10−14) 6.6 (7.5 × 10−9) 18.3 (6.0 × 10−28) 6.7 (4.7 × 10−9) 6.4 (1.7 × 10−8) 12.2 (7.5 × 10−19)
Cohen’s kappa, biased 61.0 ± 6.8 63.6 ± 12.2 68.4 ± 10.5 45.6 ± 19.7 69.6 ± 13.2 64.5 ± 20.9 54.5 ± 19.8
Cohen's kappa, unbiased 57.7 ± 6.1 61.3 ± 11.2 64.6 ± 10.3 43.5 ± 19.2 64.6 ± 13.1 60.9 ± 16.9 51.6 ± 16.7
Model kappa on concensus — 74.3 ± 12.3 72.4 ± 12.1 76.0 ± 11.8 72.7 ± 12.0 74.7 ± 12.1 76.6 ± 12.2
T-stat (p value) — 9.5 (4.6 × 10−14) 7.1 (7.9 × 10−10) 15.4 (7.0 × 10−24) 6.6 (6.4 × 10−9) 7.1 (9.2 × 10−10) 13.2 (2.0 × 10−20)
Both accuracy and Cohen’s kappa are presented as both with (biased) and without (unbiased) the assessed scorer included in the consensus standard in a leave-one-out fashion. Accuracy is expressed
in percent, and Cohen’s kappa is a ratio, and therefore unitless. T-statistics and p values correspond to the paired t-test between the unbiased predictions for each scorer against the model predictions on
the same consensus
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in Methods). On these epochs, the AASM ISR achieved a 90%
agreement between scorers. In comparison, the model estimates
reached a 95% accuracy compared to the AASM consensus
(Fig. 2b). Using the model ensemble and reporting on sleep stage
probabilities and inter-model variance for quality purpose
constitute the core of our sleep scoring algorithm.
Ensemble/best model performance. Supplementary Table 2
reports on concordance for our best model, the ensemble of all
CC models. Concordance is presented in a weighted and
unweighted manner, between the best model estimate and scorer
consensus (Table 3). Weighing of a segment was based on scorer
conﬁdence and serves to weigh down controversial segments. For
each recording i, the epoch-speciﬁc weight ωn and weighted
accuracy αω were calculated as:
ωn ¼ maxz2Z P ynjxn
 
z
 
 ‘2Z P ynjxn
  
; ð2Þ
αðiÞω ¼
1P
n ωn
X
n
ωn  argmaxm2M Pm bynjxn  
\ argmaxz2Z Pz ynjxn
  
;
ð3Þ
where ‘2Z P ynjxn
  
is the second most likely stage assessed by
the set of scorers (experts) denoted by Z, of the nth epoch in a
sleep recording. As with scorers, the biggest discrepancies
occurred between wake versus N1, N1 versus N2 and N2 versus
N3. Additionally, the weighted performance was almost uni-
versally better than the unweighted performance, raising overall
accuracy from 87 to 94%, indicating a high consensus between
automatic scoring and scorers in places with high scorer con-
ﬁdence. An explanation for these results could be that both
scorers and model are forced to make a choice between two stages
when data are ambiguous. An example of this may be seen in
Fig. 2a. Between 1 and 3 h, several bouts of N3 occur, although
they often do not reach the threshold for being the most likely
stage. As time progresses, more evidence for N3 appears reﬂecting
increased proportion of slow waves per epoch, and conﬁdence
increases, which ﬁnally yields “deﬁnitive” N3. This is seen in both
model and scorer estimates. Choosing to present the data as
hypnodensity graphs mitigates this problem. The various model
estimates produce similar results, which also resemble the scorer
assessment distribution, although models without memory ﬂuc-
tuate slightly more, and tend to place a higher probability on
REM sleep in periods of wakefulness, since no contextual infor-
mation is provided.
Inﬂuences of sleep pathologies. As seen in Table 2, the different
cohorts achieve different performances. To see how much may be
attributed to various pathologies, ﬁve different analyses of var-
iance were made, with accuracy as the dependent variable, using
cohort, age (grouped as age < 30, 30 ≤ age < 50 and age ≥ 50) and
sex as covariates (Supplementary Table 4), investigating the effect
of insomnia, OSA, restless leg syndrome (RLS), periodic leg
movement index (PLMI) and T1N on accuracy of our machine
learning routine versus human scoring. This was performed in
the cohort mentioned above with addition of the Austrian
Hypersomnia Cohort (AHC)35. The p values obtained from
paired t-testing for each condition were 0.75 (insomnia), 7.53 ×
10−4 (OSA), 0.13 (RLS), 0.22 (PLMI) and 1.77 × 10−15 (T1N)
respectively, indicating that only narcolepsy had a strong effect on
scorer performance. Additionally, in the context of narcolepsy,
cohort and age yielded p values between 3.69 × 10−21 and 2.81 ×
10−82 and between 0.62 and 6.73 × 10−6, respectively. No sig-
niﬁcant effect of gender was ever noted. Cohort effects were
expected and likely reﬂect local scorer performances and differ-
ences in PSG hardware and ﬁlter setups at every site. Decreased
performance with age likely reﬂects decreased EEG amplitude,
notably in N3/slow wave sleep amplitude with age36.
Table 2 Performance of best models, as they are described by Supplementary Table 8, on various datasets compared to the six-
scorer consensus
Test data Best single model Mean performance (%) Best ensemble Mean performance (%)
WSC CC/SH/LS/LSTM/2 86.0 ± 5.0 All CC 86.4 ± 5.2
SSC+KHC, no narcolepsy CC/LH/SS/LSTM 76.9 ± 11.1 All CC 77.0 ± 11.9
SSC+KHC, narcolepsy CC/LH/SS/LSTM 68.8 ± 11.0 All CC 68.4 ± 12.2
IS-RC CC/LH/LS/LSTM/2 84.6 ± 4.6 All models 86.8 ± 4.3
All comparisons are on a by-epoch basis
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Fig. 1 Accuracy per scorer and by time resolution. a The effect on scoring accuracy as golden standard is improved. Every combination of N scorers is
evaluated in an unweighted manner and the mean is calculated. Accuracy is shown with mean (solid black line) and a 95% conﬁdence interval (gray area).
b Predictive performance of best model at different resolutions. Performance is shown as mean accuracy (solid black line) with a 95% conﬁdence interval
(gray area)
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Resolution of sleep stage scoring. Epochs are evaluated with a
resolution of 30 s, a historical standard that is not founded in
anything physiological, and limits the analytical possibilities of a
hypnogram. Consequently, it was examined to what extent the
performance would change as a function of smaller resolution.
Only the models using a segment size of 5 s were considered.
Segments were averaged to achieve performances at 5, 10, 15 and
30 s resolutions, and the resulting performances in terms of
accuracy are shown in Fig. 1b. Although the highest performance
was found using a resolution of 30 s, performance dropped only
slightly with decreasing window sizes.
Construction and evaluation of a narcolepsy biomarker. The
neural networks produce outputs that depend on evidence in
1 Multiscorer assessment
AASMI ISR
Model variance
Average model estimateAll models
Models with memory
Models without memory
CC/LH/LS/LSTM
CC/LH/LS/FF
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Fig. 2 Hypnodensity example evaluated by multiple scorers and different predictive models. a The ﬁgure displays the hypnodensity graph. Displayed
models are, in order: multiple scorer assessment (1); ensembles as described in Supplementary Table 8: All models, those with memory (LSTM) and those
without memory (FF) (2–4); single models, as described in Supplementary Table 8 (5–7). OCT is octave encoding, Color codes: white, wake; red, N1; light
blue, N2; dark blue, N3; black, REM. b The 150 epochs of a recording from the AASM ISR program are analyzed by 16 models with randomly varying
parameters, using the CC/SH/LS/LSTM model as a template. These data were also evaluated by 5234 ± 14 different scorers. The distribution of these is
shown on top, the average model predictions are shown in the middle, and the model variance is shown at the bottom
Table 3 Confusion matrix displaying the relation between different targets and the ensemble estimate
Target
Model Predictions Wake N1 N2 N3 REM Precision
Wake 14.08% 0.35% 0.88% 0.007% 0.08% 0.91
16.68% 0.15% 0.44% 0.003% 0.02% 0.96
N1 1.13% 1.78% 3.00% 0.002% 0.36% 0.28
0.47% 0.88% 1.15% 0% 0.12% 0.34
N2 0.29% 0.59% 52.58% 1.27% 0.66% 0.95
0.12% 0.25% 56.30% 0.34% 0.32% 0.98
N3 0.002% 0% 2.13% 4.87% 0% 0.70
0% 0% 1.09% 4.23% 0% 0.91
REM 0.54% 1.17% 0.78% 0% 13.45% 0.84
0.40% 0.73% 0.41% 0% 15.86% 0.91
Sensitivity 0.88 0.46 0.89 0.79 0.92 0.87
0.94 0.44 0.95 0.92 0.97 0.94
The targets are: top row: unweighted consensus; bottom row: weighted by the scorer agreement at each epoch. The number of analyzed epochs were 53,009 (unweighted) and 36,032 (weighted)
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the input data for or against a certain sleep stage based on
features learned through training. We hypothesized that nar-
colepsy, a condition characterized by sleep/wake stage mixing/
dissociation37−41, would result in a greater than normal
overlap between stages, an observation that was obvious when
sleep stage probability were plotted in such subjects (see
example in Fig. 3). Based on this result, we hypothesized that
such sleep stage model outputs could be used as a biomarker
for the diagnosis of narcolepsy using a standard nocturnal
PSG rather than the more time-consuming MSLT.
To quantify narcolepsy-like behavior for a single recording, we
generated features quantifying sleep stage mixing/dissociation.
These are based on descriptive statistics and other features
describing persistence of a set of new time series generated from
the geometric mean of every permutation of the set of sleep
stages, as obtained from the 16 CC sleep stage prediction models.
In addition to this, we also added features expected to predict
narcolepsy based on prior work, such as REM sleep latency and
sleep stage sequencing parameters (see “Hypnodensity as feature
for the diagnosis of T1N” section in Methods for details). A
recursive feature elimination (RFE) procedure42 was performed
on extracted features with average outcome putting the optimal
number of relevant features at 38. An optimal selection frequency
cut-off of 0.40 (i.e., including a feature if it was selected 40% of
the time) was determined using a cross-validation setup on the
training data. Features are described in Supplementary Table 5
with detailed description of the 8 most important features
reported in Table 4.
Final predictions were achieved by creating a separate
Gaussian Predictor (GP) narcolepsy classiﬁer from each of
the sleep scoring models used in the ﬁnal implementation. This
was tested in seven independent datasets: a training dataset
constituted of PSG from WSC32,33, SSC10,32, KHC10,34, AHC35,
Jazz Clinical Trial Sample (JCTS)43, Italian Hypersomnia
Cohort (IHC)41 and DHC; with veriﬁcation in test data mostly
constituted of PSG from the same cohorts and independent
replication in the French Hypersomnia Cohort (FHC) and the
Chinese Narcolepsy Cohort (CNC)12 that had never been seen
by the algorithm (see Supplementary Table 1). The algorithm
produced values between −1 and 1, with 1 indicating a high
probability of narcolepsy. A cut-off threshold between narco-
lepsy type 1 and “other“ was set at −0.03 (red dot, Fig. 4),
determined using training data, as shown in Fig. 4a. The
optimal trade-off achieves both high sensitivity and speciﬁcity,
which is seen to translate well onto the test data (Fig. 4b) and
the never seen replication sample (Fig. 4c).
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Fig. 3 Examples of hypnodensity graph in subjects with and without narcolepsy. Hypnodensity, i.e., probability distribution per stage of sleep for a subject
without narcolepsy (top) and a subject with narcolepsy (Bottom). Color codes: white, wake; red, N1; light blue, N2; dark blue, N3; black, REM
Table 4 Descriptions of the 8 most frequently selected features
Number Relative selection
frequency
Description
1 1 The time taken before 5% of the sum of the product between W, N2 and REM, calculated at every epoch, has
accumulated, weighed by the total amount of this sum.
This feature expresses the known sleep stage dissociation and altered sleep timing.
2 0.91 The number of nightly SOREMPS appearing throughout the recording.
3 0.82 The time taken before 50% of the wakefulness in a recording has accumulated, weighed by the total amount of
wakefulness.
4 0.82 REM 6
The Shannon entropy of the REM sleep stage distribution. This expresses the amount of information held in a
signal, or in this case, how many different values the REM sleep stage distribution obtains—how consolidated
phases of REM are when the stage appears.
5 0.68 The maximum probability of wakefulness obtained in a recording.
6 0.68 The maximum value obtained of the product between the N2 and REM probability in a recording.
7 0.68 The time taken before 30% of the sum of the product between W and N2, calculated at every epoch, has
accumulated, weighed by the total amount of this sum.
8 0.64 The time taken before 10% of the sum of the product between W and N1, calculated at every epoch, has
accumulated, weighed by the total amount of this sum.
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In the training data, a sensitivity of 94% and speciﬁcity of
96% was achieved, and in the testing data a sensitivity of 91%
and speciﬁcity of 96% was achieved, while the sensitivity
and speciﬁcity for the replication sample was 93 and 91%,
respectively. When human leukocyte antigen (HLA) was added to
this model (Fig. 4d–f), the sensitivity became 90% and the
speciﬁcity rose to 99%, and an updated cut-off threshold of −0.53
was determined (green dot, Fig. 4d–f). Furthermore, in the high
pretest sample we obtained a sensitivity and speciﬁcity of 90 and
92%, which rose to 90 and 98% when adding HLA. More
descriptive statistics including 95% conﬁdence intervals are found
in Supplementary Table 6.
Discussion
In recent years, machine learning has been used to solve similar or
more complex problems, such as labeling images, understanding
speech and translating language, and have seen advancement to
the point where humans are now sometimes outperformed21–23,
while also showing promising results in various medical
ﬁelds24–29. Automatic classiﬁcation of sleep stages using automatic
algorithms is not novel44,45, but only recently has this type of
machine learning been applied and the effectiveness has only been
demonstrated in a small numbers of sleep studies46–49. Because
PSGs contain large amounts of manually annotated “gold stan-
dard” data, we hypothesized this method would be ideal to
automatize sleep scoring. We have shown that machine learning
can be used to score sleep stages in PSGs with high accuracy in
multiple physical locations in various recording environments,
using different protocols and hardware/software conﬁgurations,
and in subjects with and without various sleep disorders.
After testing various machine learning algorithms with and
without memory and speciﬁc encodings, we found increased
robustness using a consensus of multiple algorithms in our pre-
diction. The main reason for this is likely the sensitivity of each
algorithm to particular aspects of each individual recording,
resulting in increased or decreased predictability. Supplementary
Figure 1b displays the correlations between different models.
Models that incorporate an ensemble of different models generally
have a higher overall correlation coefﬁcient than singular models,
and since individual models achieve similar performances, it
stands to reason that these would achieve the highest performance.
One potential source for this variability was, in addition to the
stochastic nature of the training, the fact recordings were con-
ducted in different laboratories that were using different hardware
and ﬁlters, and had PSGs scored by technicians of various abilities.
Another contributor was the presence of sleep pathologies in the
dataset that could inﬂuence machine learning. Of the pathologies
tested, only narcolepsy had a very signiﬁcant effect on the corre-
spondence between manual and machine learning methods (p=
1.77 × 10−15 vs p= 7.53 × 10−4 for sleep apnea for example)
(Supplementary Tables 4 and 7). This was not surprising as the
pathology is characterized by unusual sleep stage transitions, for
example, transitions from wake to REM sleep, which may make
human or machine learning staging more difﬁcult. This result
suggests that reporting inter-model variations in accuracy for each
speciﬁc patient has value in ﬂagging unusual sleep pathologies, so
this metric is also reported by our detector.
Unlike previous attempts using automatic detector validations,
we were able to include 70 subjects scored by 6 technicians in
different laboratories (the IS-RC cohort)31 to independently
validate our best automatic scoring consensus algorithm. This
allowed us to estimate the performance at 87% in comparison to
the performance of a consensus score for every epoch among six
expert technicians (ultimate gold standard) (Table 1). Including
more scorers produces a better gold standard, and as Fig. 1a
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Fig. 4 Diagnostic receiver operating characteristics curves. Diagnostic receiver operating characteristics (ROC) curves, displaying the trade-offs between
sensitivity and speciﬁcity for our narcolepsy biomarker for a training sample, b testing sample, c replication sample and e high pretest sample. d–f Adding
HLA to model vastly increases speciﬁcity. Cut-off thresholds are presented for models with (red dot) and without HLA (green dot)
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indicates, the model accuracy also increases with more scorers.
Naturally, extrapolating from this should be done with caution;
however, it is reasonable to assume that the accuracy would
continue to increase with increased scorers. In comparison, per-
formance of any individual scorer ranges from 74 to 85% when
compared to the same six-scorer gold standard, keeping in mind
this performance is artiﬁcially inﬂated since the same scorers
evaluated are included in the gold standard (unbiased perfor-
mance of any scorer versus consensus of remaining 5 scorers
range from 69 to 80%. The best model achieves 87% accuracy
using 5 scorers (Fig. 1a and Table 1), and is statistically higher
than all scorers. As with human scorers, the biggest discrepancies
in machine learning determination of sleep stages occurred
between wake versus N1, N1 versus N2 and N2 versus N3. This is
logical as these particular sleep stage transitions are part of a
continuum, artiﬁcially deﬁned and subjective. To give an exam-
ple: an epoch comprised of 18% slow wave activity is considered
N2 while an epoch comprised of 20% slow wave activity qualiﬁes
as N3. Overall, data indicate that our machine learning algorithm
performs better than individual scorers, as typically used in
clinical practice, or similar to the best of 5 scorers in comparison
to a combination of 5 experts scoring each epoch by consensus. It
is also able to score at higher resolution, i.e., 5 s, making it
unnecessary to score sleep stages by 30 s epochs, an outdated rule
dating from the time sleep was scored on paper. Although the
data sample used for multi-scorer validation contained only
female subjects, the scoring accuracy of our model was not seen to
be affected by gender (Supplementary Table 3) in another
analysis.
Using our models, and considering how typical T1N behaved
in our sleep stage machine learning routines, we extracted fea-
tures that could be useful to diagnose this condition. T1N is
characterized by the loss of hypocretin-producing cells in the
hypothalamus3 and can be best diagnosed by measuring hypo-
cretin levels in the CSF11, a procedure that requires a lumbar
puncture, a rarely performed procedure in the United States. At
the symptomatic level, T1N is characterized by sleepiness, cata-
plexy (episodes of muscle weakness during wakefulness triggered
by emotions) and numerous symptoms reﬂecting poor nocturnal
sleep (insomnia) and symptoms of “dissociated REM sleep”.
Dissociated REM sleep is reﬂected by the presence of unusual
states of consciousness where REM sleep is intermingled with
wakefulness, producing disturbing reports of dreams that inter-
rupt wakefulness and seem real (dream-like hallucinations), or
episodes where the sleeper is awake but paralyzed as in normal
REM sleep (sleep paralysis). The current gold standard for T1N
diagnosis is the presence of cataplexy and a positive MSLT. In a
recent large study of the MSLT, speciﬁcity and sensitivity for T1N
was 98.6% and 92.9% in comparing T1N versus controls, and
71.2% and 93.4% in comparing T1N versus other hypersomnia
cases (high pretest probability cohort)10.
Table 4 and Supplementary Table 5 reveal features found in
nocturnal PSGs that discriminate type 1 narcoleptics and non-
narcoleptics. One of the most prominent features, short latency
REM sleep, bears great resemblance to the REM sleep latency,
which is already used clinically to diagnose narcolepsy, although
in this case it is calculated using fuzzy logic and thus represent a
latency where accumulated sleep is suggestive of a high prob-
ability of REM sleep having occurred (as opposed to a discrete
REM latency scored by a technician). A short REM latency during
nocturnal PSG (typically 15 min) has recently been shown to be
extremely speciﬁc (99%) and moderately sensitive (40–50%) for
T1N10,50. The remaining selected features also describe a gen-
erally altered sleep architecture, particularly between REM sleep,
light sleep and wake, aspects of narcolepsy already known and
thus reinforcing their validity as biomarkers.
For example, the primary feature as determined by the RFE
algorithm was the time taken until 5% of the accumulated sum of
the probability products between stages W, N2 and REM had
been reached (see also Table 4), which reﬂects the uncertainty
between wakefulness, REM and N2 sleep at the beginning of the
night. Speciﬁcally, for the nth epoch, the model will output
probabilities for each sleep stage, and the proto-feature Φn is
calculated as
Φn ¼ p Wð Þ ´ p N2ð Þ þ p Wð Þ ´ p REMð Þ þ pðN2Þ ´ pðREMÞ:
ð4Þ
The feature value is then calculated as the time it takes in
minutes for the accumulated sum of Φn to reach 5% of the total
sum
P
nΦn. Since each of probability product in Φn reﬂects the
staging uncertainty between each sleep stage pair, Φn alone
reﬂects the general sleep stage uncertainty for that speciﬁc epoch
as predicted by the model. A very high value will be attained for
epoch n if the probabilities for N2, W and REM are equally
probable with probabilities for the remaining sleep stages being
low or close to zero. A PSG with a high staging uncertainty
between sleep and wake early in the night would reach the 5%
threshold rapidly.
Using these features, we were able to determine an optimal cut-
off that discriminated narcolepsy from controls and any other
patients with as high speciﬁcity and sensitivity as the MSLT
(Supplementary Table 6), notably when HLA typing is added.
This is true for both the test and the never seen replication
samples. Although we do observe a small drop in speciﬁcity in the
replication sample, the efﬁcacy of the detector was also tested in
the context of naive patients with hypersomnia (high pretest
probability sample), and performance found to be similar to the
MSLT.
MSLT testing requires that patients spend an entire night and
day in a sleep laboratory. The use of this novel biomarker could
reduce time spent to a standard 8 h night recording, as done for
the screening of other sleep pathologies (e.g., OSA), allowing
improved recognition of T1N cases at a fraction of the cost. A
positive predictive value could also be provided depending on the
nature of the sample and known narcolepsy prevalence (low in
general population screening, intermediary in overall clinic
population sample and high in hypersomnia cohorts). It also
opens the possibility of using home sleep recordings for diag-
nosing narcolepsy. In this direction, because of the probabilistic
and automatic nature of our biomarker, estimates from more
than one night could be automatically analyzed and combined
over time, ensuring improved prediction. However, it is impor-
tant to note that this algorithm will not replace the MSLT in the
ability to predict excessive daytime sleepiness through the mea-
sure of mean sleep latency across daytime naps, which is an
important characteristic of other hypersomnias.
In conclusion, models which classify sleep by assigning a
membership function to each of ﬁve different stages of sleep for
each analyzed segment were produced, and factors contributing
to the performance were analyzed. The models were evaluated on
different cohorts, one of which contained 70 subjects scored by 6
different sleep scoring technicians, allowing for inter-scorer
reliability assessments. The most successful model, consisting of
an ensemble of different models, achieved an accuracy of 87% on
this dataset, and was statistically better performing than any
individual scorer. It was also able to score sleep stages with high
accuracy at lower time resolution (5 s), rendering the need for
scoring per 30 s epoch obsolete. When predictions were weighted
by the scorer agreement, performance rose to 95%, indicating a
high consensus between the model and human scorers in areas of
high scorer agreement. A ﬁnal implementation was made using
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an ensemble with small variations of the best single model. This
allowed for better predictions, while also providing a measure of
uncertainty in an estimate.
When the staging data were presented as hypnodensity dis-
tributions, the model conveyed more information about the
subject than through a hypnogram alone. This led to the creation
of a biomarker for narcolepsy that achieved similar performance
to the current clinical gold standard, the MSLT, but only requires
a single sleep study. If increased speciﬁcity is needed, for example,
in large-scale screening, HLA or additional genetic typing brings
speciﬁcity above 99% without loss of sensitivity. This presents an
option for robust, consistent, inexpensive and simpler diagnosis
of subjects who may have narcolepsy, as such tests may also be
carried out in a home environment.
This study shows how hypnodensity graphs can be created
automatically from raw sleep study data, and how the resulting
interpretable features can be used to generate a diagnosis prob-
ability for T1N. Another approach would be to classify narcolepsy
directly from the neural network by optimizing the performance
not only for sleep staging, but also for direct diagnosis by adding
an additional softmax output, thereby creating a multitask clas-
siﬁer. This approach could lead to better predictions, since fea-
tures are not then limited to by a designer imagination. A
drawback of this approach is that features would no longer be as
interpretable and meaningful to clinicians. If meaning could be
extracted from these neural network generated features, this
might open the door to a single universal sleep analysis model,
covering multiple diseases. Development of such a model would
require adding more subjects with narcolepsy and other condi-
tions to the pool of training data.
Methods
Datasets. The success of machine learning depends on the size and quality of the
data on which the model is trained and evaluated51,52. We used a large dataset
comprised of several thousand sleep studies to train, validate and test/replicate our
models. To ensure signiﬁcant heterogeneity, data came from 10 different cohorts
recorded at 12 sleep centers across 3 continents: SSC10,32, WSC32,33, IS-RC31,
JCTS43, KHC10,34, AHC35, IHC41, DHC53, FHC and CNC12. Institutional review
boards approved the study and informed consent was obtained from all partici-
pants. Technicians trained in sleep scoring manually labeled all sleep studies.
Figure 5a–c summarizes the overall design of the study for sleep stage scoring and
narcolepsy biomarker development. Supplementary Table 1 provides a summary of
the size of each cohort and how it was used. In the narcolepsy biomarker aspect of
the study, PSGs from T1N and other patients were split across most datasets to
ensure heterogeneity in both the training and testing datasets. For this analysis, a
few recordings with poor quality sleep studies, i.e., missing critical channels, with
additional sensors or with a too short sleep duration (≤2 h) were excluded. A
“never seen” subset cohort that included French and Chinese subjects (FHC and
CNC) was also tested. Below is a brief description of each dataset.
Population-based Wisconsin Sleep Cohort. This cohort is a longitudinal study of
state agency employees aged 37–82 years from Wisconsin, and it approximates a
population-based sample (see Supplementary Table 1 for age at study) except for
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Fig. 5 Overall design of the study. a Pre-processing steps taken to achieve the format of data as it is used in the neural networks. One of the 5 channels is
ﬁrst high-pass ﬁltered with a cut-off at 0.2 Hz, then low-pass ﬁltered with a cut-off at 49 Hz followed by a re-sampling to 100 Hz to ensure data
homogeneity. In the case of EEG signals, a channel selection is employed to choose the channel with the least noise. The data are then encoded using either
the CC or the octave encoding. b Steps taken to produce and test the automatic scoring algorithm. A part of the SSC10, 32 and WSC32, 33 is randomly
selected, as described in Supplementary Table 1. These data are then segmented in 5min segments and scrambled with segments from other subjects to
increase batch similarity during training. A neural network is then trained until convergence (evaluated using a separate validation sample). Once trained,
the networks are tested on a separate part of the SSC and WSC along with data from the IS-RC31 and KHC10, 34. c Steps taken to produce and test the
narcolepsy detector. Hypnodensities are extracted from data, as described in Supplementary Table 1. These data are separated into a training (60%) and a
testing (40%) split. From the training split, 481 potentially relevant features, as described in Supplementary Table 9, are extracted from each hypnodensity.
The prominent features are maintained using a recursive selection algorithm, and from these features a GP classiﬁer is created. From the testing split, the
same relevant features are extracted, and the GP classiﬁer is evaluated
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the fact they are generally more overweight33. The study is ongoing, and dates to
1988. The 2167 PSGs in 1086 subjects were used for training, while 286 randomly
selected PSGs were used for validation testing of the sleep stage scoring algorithm
and narcolepsy biomarker training. Approximately 25% of the population have an
Apnea Hypopnea Index (AHI) above 15/h and 40% have a PLMI above 15/h. A
detailed description of the sample can be found in Young et al.33 and Moore
et al.32. The sample does not contain any T1N patients, and the three subjects with
possible T1N were removed54.
Patient-based Stanford Sleep Cohort. PSGs from this cohort were recorded at
the Stanford Sleep Clinic dating back to 1999, and represent sleep disorder patients
aged 18–91 years visiting the clinic (see Supplementary Table 1 for age at study).
The cohort contains thousands of PSG recordings, but for this study we used 894
diagnostic (no positive airway pressure) recordings in independent patients that
have been used in prior studies30. This subset contains patients with a range of
different diagnoses including: sleep disordered breathing (607), insomnia (141),
REM sleep behavior disorder (4), restless legs syndrome (23), T1N (25), delayed
sleep phase syndrome (14) and other conditions (39). Description of the subsample
can be found in Andlauer et al.10 and Moore et al.32. Approximately 30% of
subjects have an AHI above 15/h, or a PLMI above 15/h. The 617 randomly
selected subjects were used for training the neural networks, while 277 randomly
selected PSGs were kept for validation testing of the sleep stage scoring algorithm.
These 277 subjects were also used for training the narcolepsy biomarker algorithm.
The sample contains PSGs of 25 independent untreated subjects with T1N (12 with
low CSF hypocretin-1, the others with clear cataplexy). A total of 26 subjects were
removed from the study—4 due to poor data quality, and the rest because of
medication use.
Patient-based Korean Hypersomnia Cohort. The Korean Hypersomnia Cohort is
a high pretest probability sample for narcolepsy. It includes 160 patients with a
primary complaint of excessive daytime sleepiness (see Supplementary Table 1 for
age at study). These PSGs were used for testing the sleep scoring algorithm and for
training the narcolepsy biomarker algorithm. No data were used for training the
sleep scoring algorithm. Detailed description of the sample can be found in Hong
et al.34 and Andlauer et al.10. The sample contains PSGs of 66 independent
untreated subjects with T1N and clear cataplexy. Two subjects were removed from
the narcolepsy biomarker study because of poor data quality.
Patient-based Austrian Hypersomnia Cohort. Patients in this cohort were
examined at the Innsbruck Medical University in Austria as described in Frauscher
et al.35. The AHC contains 118 PSGs in 86 high pretest probability patients for
narcolepsy (see Supplementary Table 1 for details). The 42 patients (81 studies) are
clear T1N with cataplexy cases, with all but 3 having a positive MSLT (these three
subjects had a MSL >8 min but multiple SOREMPs). The rest of the sample has
idiopathic hypersomnia and type 2 narcolepsy. Four patients have an AHI >15/h
and 25 had a PLMI >15/h. Almost all subjects had two sleep recordings performed,
which were kept together such that no two recordings from the same subject were
split between training and testing partitions.
Patient-based Inter-scorer Reliability Cohort. As Rosenberg and Van Hout16
have shown, variation between individual scorers can sometimes be large, leading
to an imprecise gold standard. To quantify this, and to establish a more accurate
gold standard, 10 scorers from 5 different institutions, University of Pennsylvania,
St. Luke’s Hospital, University of Wisconsin at Madison, Harvard University and
Stanford University, analyzed the same 70 full-night PSGs. For this study, scoring
data from University of Pennsylvania, St. Luke’s and Stanford were used. All
subjects are female (see Supplementary Table 1 for details). This allowed for a
much more precise gold standard, and the inter-scorer reliability could be quan-
tiﬁed for a dataset, which could also be examined by automatic scoring algorithms.
Detailed description of the sample can be found in Kuna et al.31 and Malhotra and
Avidan6. The sample does not contain any T1N patients.
The Jazz Clinical Trial Sample. This sample includes 7 baseline sleep PSGs from
5 sites taken from a clinical trial study of sodium oxybate in narcolepsy (SXB15
with 45 sites in Canada, United States, and Switzerland) conducted by Orphan
Medical, now named Jazz Pharmaceuticals. The few patients included are those
with clear and frequent cataplexy (a requirement of the trial) who had no stimulant
or antidepressant treatment at baseline43. All seven subjects in this sample were
used exclusively for training the narcolepsy biomarker algorithm.
Patient-based Italian Hypersomnia Cohort. Patients in this high pretest prob-
ability cohort (see Supplementary Table 1 for demographics) were examined at the
IRCCS, Istituto delle Scienze Neurologiche ASL di Bologna in Italy as described in
Pizza et al.41. The IHC contains 70 T1N patients (58% male, 29.5 ± 1.9 years old),
with either documented low CSF hypocretin levels (59 cases, all but 2 HLA-
DQB1*06:02 positive) or clear cataplexy, positive MSLTs and HLA positivity
(11 subjects). As non-T1N cases with unexplained daytime somnolence, the cohort
includes 77 other patients: 19 with idiopathic hypersomnia, 7 with type 2
narcolepsy and normal CSF hypocretin-1, 48 with a subjective complaint of
excessive daytime sleepiness not conﬁrmed by MSLT and 3 with secondary
hypersomnia. Subjects in this cohort were used for training (n= 87) and testing
(n= 61) the narcolepsy biomarker algorithm.
Patient-based Danish Hypersomnia Cohort. Patients in this cohort were examined
at the Rigshospitalet, Glostrup, Denmark, as described in Christensen et al.53. The DHC
contains 79 PSGs in controls and patients (see Supplementary Table 1 for details). Based
on PSG, multiple sleep latency test and cerebrospinal ﬂuid hypocretin-1 measures, the
cohort includes healthy controls (19 subjects), patients with other sleep disorders and
excessive daytime sleepiness (20 patients with CSF hypocretin-1 ≥110 pg/ml), narco-
lepsy type 2 (22 patients with CSF hypocretin-1 ≥110 pg/ml), and T1N (28 patients with
CSF hypocretin-1 ≤110 pg/ml). All 79 subjects in this cohort were used exclusively for
training the narcolepsy biomarker algorithm.
Patient-based French Hypersomnia Cohort. This cohort consists of 122 indivi-
dual PSGs recorded at the Sleep-Wake Disorders Center, Department of Neurol-
ogy, Gui-de-Chauliac Hospital, CHU Montpellier, France (see Supplementary
Table 1 for demographics). The FHC contains 63 subjects with T1N (all but two
tested with CSF hypocretin-1 ≤110 pg/ml, ﬁve below 18 years old, 55 tested for
HLA, all positive for HLA-DQB1*06:02) and 22 narcolepsy type 2 (19 with CSF
hypocretin-1 >200 pg/ml, and three subjects with CSF hypocretin-1 between 110
and 200 pg/ml, three HLA positive). The remaining 36 subjects are controls (15
tested for HLA, two with DQB1*06:02) without other symptoms of hypersomnia.
The FHC was used as data for the replication study of the narcolepsy biomarker
algorithm.
Patient-based Chinese Narcolepsy Cohort. This cohort contains 199 individual
PSGs recorded (see Supplementary Table 1 for demographics). The CNC contains
67 subjects diagnosed with T1N exhibiting clear-cut cataplexy (55 tested HLA-
DQB1*06:02 positive), while the remaining 132 subjects are randomly selected
population controls (15 HLA-DQB1*06:02 positive, 34 HLA negative, remaining
unknown)12. Together with the FHC, the CNC was used as data for the replication
study of the narcolepsy biomarker algorithm.
American Academy of Sleep Medicine Sleep Study. The AASM ISR dataset is
composed of a single control sleep study of 150 30 s epochs that was scored by
5234 ± 14 experienced sleep technologists for quality control purposes. Design of
this dataset is described in Rosenberg and Van Hout16.
Data labels, scoring and fuzzy logic. Sleep stages were scored by PSG-trained
technicians using established scoring rules, as described in the AASM Scoring
Manual7. In doing so, technicians assign each epoch with a discrete value. With a
probabilistic model, like the one proposed in this study, a relationship to one of the
fuzzy sets is inferred based on thousands of training examples labeled by many
different scoring technicians.
The hypnodensity graph refers to the probability distribution over each possible
stage for each epoch, as seen in Fig. 2a, b. This allows more information to be
conveyed, since every epoch of sleep within the same stage is not identical. For
comparison with the gold standard, however, a discrete value must be assigned
from the model output as:
y^ ¼ argmaxyi
XN
i
Pi yijxi
 
; ð5Þ
where PiðyijxiÞ is a vector with the estimated probabilities for each sleep stage in
the ith segment, N is the number of segments an epoch is divided into and y^ is the
estimated label.
Sleep scoring technicians score sleep in 30 s epochs, based on what stage they
assess is represented in the majority of the epoch—a relic of when recordings were
done on paper. This means that when multiple sleep stages are represented, more
than half of the epoch may not match the assigned label. This is evident in the fact
that the label accuracy decreases near transition epochs20. One solution to this
problem is to remove transitional regions to purify each class. However, this has
the disadvantage of under-sampling transitional stages, such as N1, and removes
the context of quickly changing stages, as is found in a sudden arousal. It has been
demonstrated that the negative effects of imperfect “noisy” labels may be mitigated
if a large enough training dataset is incorporated and the model is robust to
overﬁtting41. This also assumes that the noise is randomly distributed with an
accurate mean—a bias cannot be canceled out, regardless of the amount of training
data. For these reasons, all data including those containing sleep transitions were
included. Biases were evaluated by incorporating data from several different
scoring experts cohorts and types of subjects.
To ensure quick convergence, while also allowing for long-term dependencies in
memory-based models, the data were broken up in 5 min blocks and shufﬂed to
minimize the shift in covariates during training caused by differences between
subjects. To quantify the importance of segment sizes, both 5 s and 15 s windows
were also tested.
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Data selection and pre-processing. A full-night PSG involves recording many
different channels, some of which are not necessary for sleep scoring55. In this
study, EEG, C3 or C4, and O1 or O2, chin EMG and the left and right EOG
channels were used, with reference to the contralateral mastoid. Poor electrode
connections are common when performing a PSG analysis. This can lead to a noisy
recording, rendering it useless. To determine whether right or left EEG channels
were used, the noise of each was quantiﬁed by dividing the EEG data in 5 min
segments, and extracting the Hjorth parameters56. These were then log-trans-
formed, averaged and compared with a previously established multivariate dis-
tribution, based on the WSC32,33 and SSC10,32 training data. The channel with
lowest Mahalanobis distance57 to this distribution was selected. The log transfor-
mation has the advantage of making ﬂat signals/disconnects as uncommon as very
noisy signals, in turn making them less likely to be selected. To minimize het-
erogeneity across recordings, and at the same time reducing the size of the data, all
channels were down-sampled to 100 Hz. Additionally, all channels were ﬁltered
with a ﬁfth-order two-direction inﬁnite impulse response (IIR) high-pass ﬁlter with
cut-off frequency of 0.2 Hz and a ﬁfth-order two-direction IIR low-pass ﬁlter with
cut-off frequency of 49 Hz. The EMG signal contains frequencies well above 49 Hz,
but since much data had been down-sampled to 100 Hz in the WSC, this cut-off
was selected for all cohorts. All steps of the pre-processing are illustrated in Fig. 5a.
Convolutional and recurrent neural networks. Convolutional neural networks
(CNNs) are a class of deep learning models ﬁrst developed to solve computer vision
problems30. A CNN is a supervised classiﬁcation model in which a low level, such
as an image, is transformed through a network of ﬁlters and sub-sampling layers.
Each layer of ﬁlters produces a set of features from the previous layer, and as more
layers are stacked, more complex features are generated. This network is coupled
with a general-purpose learning algorithm, resulting in features produced by the
model reﬂecting latent properties of the data rather than the imagination of the
designer. This property places fewer constrictions on the model by allowing more
ﬂexibility, and hence the predictive power of the model will increase as more data
are observed. This is facilitated by the large number of parameters in such a model,
but may also necessitate a large amount of training data. Sleep stage scoring
involves a classiﬁcation of a discrete time series, in which adjacent segments are
correlated. Models that incorporate memory may take advantage of this and may
lead to better overall performance by evening out ﬂuctuations. However, these
ﬂuctuations may be the deﬁning trait or anomaly of some underlying pathology
(such as narcolepsy, a pathology well known to involve abnormal sleep stages
transitions), present in only a fraction of subjects, and perhaps absent in the
training data. This can be thought of similarly to a person with a speech impe-
diment: the contextual information will ease the understanding, but knowing only
the output, this might also hide the fact that the person has such a speech impe-
diment. To analyze the importance of this, models with and without memory were
analyzed. Memory can be added to such a model by introducing recurrent con-
nections in the ﬁnal layers of the model. This turns the model into a recurrent
neural network (RNN). Classical RNNs had the problem of vanishing or exploding
gradients, which meant that optimization was very difﬁcult. This problem was
solved by changing the conﬁguration of the simple hidden node into a LSTM cell58.
Models without this memory are referred to as FF models. A more in-depth
explanation of CNNs including application areas can be found in the review article
on deep learning by LeCun et al.30 and the deep learning textbook by Goodfellow
et al.59. For a more general introduction to machine learning concepts, see the
textbook by Bishop60.
Data input and transformations. Biophysical signals, such as those found in a
PSG, inherently have a low signal to noise ratio, the degree of which varies between
subjects, and hence learning robust features from these signals may be difﬁcult. To
circumvent this, two representations of the data that could minimize these effects
were selected. An example of each decomposition is shown in Fig. 6a.
Octave encoding maintains all information in the signal, and enriches it by
repeatedly removing the top half of the bandwidth (i.e., cut-off frequencies of 49,
25, 12.5, 6.25 and 3.125 Hz) using a series of low-pass ﬁlters, yielding a total of 5
new channels for each original channel. At no point is a high-pass ﬁlter applied.
Instead, the high frequency information may be obtained by subtracting lower
frequency channels—an association the neural networks can make, given their
universal approximator properties61. After ﬁltration, each new channel is scaled to
the 95th percentile and log modulus transformed:
xscaled ¼ sign xð Þ  log
xj j
P95 xð Þ
þ 1
 
: ð6Þ
The initial scaling places 95% of the data between −1 and 1, a range in which
the log modulus is close to linear. Very large values, such as those found in
particularly noisy areas, are attenuated greatly. Some recordings are noisy, making
the 95th percentile signiﬁcantly higher than what the physiology reﬂects. Therefore,
instead of selecting the 95th percentile from the entire recording, the recording is
separated into 50% overlapping 90 min segments, from which the 95th percentile is
extracted. The mode of these values is then used as a scaling reference. In general,
scaling and normalization is important to ensure quick convergence as well as
generalization in neural networks. The decomposition is done in the same way on
every channel, resulting in 25 new channels in total.
CC encoding, using a CC function, underlying periodicities in the data are
revealed while noise is attenuated. White noise is by deﬁnition uncorrelated; its
autocorrelation function is zero everywhere except lag zero. It is this property that
is utilized, even though noise cannot always be modeled as such. PSG signals are
often obscured by undesired noise that is uncorrelated with other aspects of the
signals. An example CC between a signal segment and an extended version of the
same signal segment is shown in Supplementary Figure 5. Choosing the CC in this
manner over a standard autocorrelation function serves two purposes: the slow
frequencies are expressed better, since there is always full overlap between the two
signals (some of this can be adjusted with the normal autocorrelation function
using an unbiased estimate); and the change in ﬂuctuations over time within a
segment is expressed, making the function reﬂect aspects of stationarity. Because
this is the CC between a signal and an extended version of itself, the zero lag
represents the power of that segment, as is the case in an autocorrelation function.
Frequency content with a time resolution may also be expressed using time-
frequency decompositions, such as spectrograms or scalograms; however, one of
the key properties of a CNN is the ability to detect distinct features anywhere in an
input, given its property of equivariance62. A CC function reveals an underlying set
of frequencies as an oscillation pattern, as opposed to a spectrogram, where
frequencies are displayed as small streaks or spots in speciﬁc locations,
corresponding to frequencies at speciﬁc times. The length and size of each CC
reﬂects the expected frequency content and the limit of quasi-stationarity (i.e., how
quickly the frequency content is expected to change).
The EOG signal reveals information about eye movements such as REMs, and
to some extent EEG activity6,7. In the case of the EOG signal, the relative phase
between the two channels is of great importance to determine synchronized eye
movements, and hence a CC of opposite channels (i.e., either the extended or zero
padded signal is replaced with the opposite channel) is also included. The slowest
eye movements happen over the course of several seconds6,7, and hence a segment
length of 4 s was selected for the correlation functions. To maintain resolution
ﬂexibility with the EEG, an overlap of 3.75 s was chosen.
In the case of the EMG signal, the main concern is the signal amplitude and the
temporal resolution, not the actual frequencies. As no relevant low-frequency
content is expected, a segment length of 0.4 s and an overlap of 0.25 s was selected.
As with the octave encoding, the data are scaled, although only within segments:
Di ¼
γxiyi  log 1þmax γxiyi
  
max γxiyi
   ; ð7Þ
where Di is the scaled correlation function and γxiyi is the unscaled correlation
function.
Architectures of applied CNN models. The architecture of a CNN typically
reﬂects the complexity of the problem that is being solved and how much training
data are available, as a complex model has more parameters than a simple model,
and is therefore more likely to over-ﬁt. However, much of this may be solved using
proper regularization. Another restriction is the resources required to train a model
—deep and complex models require far more operations and will therefore take
longer to train and operate. In this study, no exhaustive hyper-parameter opti-
mization was carried out. The applied architectures were chosen on the basis of
other published models63. Since the models utilized three separate modalities (EEG,
EOG and EMG), three separate sub-networks were constructed. These were fol-
lowed by fully connected layers combining the inputs from each sub-network,
which were passed onto a softmax output (Fig. 6b, Supplementary Figure 3).
Models that utilize memory have fully connected hidden units replaced with LSTM
cells and recurrent connections added between successive segments. Networks of
two different sizes are evaluated to quantify the effect of increasing complexity.
Training of CNN models. Training the models involves optimizing parameters to
minimize a loss function evaluated across a training dataset. The loss function was
deﬁned as the cross-entropy with L2 regularization:
L ωð Þ ¼ 1
N
XN
i¼1 H yi;byi
 þ L2 ¼ 1
N
XN
i¼1 yilogbyi þ 1 yi
 
logð1 byiÞ þ λ jjωjj22;
ð8Þ
where yi is the true class label of the ith window, byi is the estimated probability of
the ith window, ω is the parameter to be updated and λ is the weight decay
parameter set at 0.00001. The model parameters were initialized with Nð0; 0:01Þ,
and trained until convergence using stochastic gradient decent with momentum64.
Weight updates were done as: ωtþ1 ¼ ωt þ ηvtþ1 with vtþ1 ¼ αvt  δEδωt where α is
the momentum set at 0.9, vt is the learning velocity, initialized at 0, and η is the
learning rate, initially set at 0.005. The learning rate was gradually reduced with an
exponential decay η ¼ η0  et=τ where t is the number of updates and τ is a time
constant, here set to 12,000.
Overﬁtting was avoided using a number of regularization techniques, including
batch normalization65, weight decay66 and early stopping67. Early stopping is
accomplished by scheduling validation after every 50th training batch. This is done
by setting aside 10% of the training data. Training is stopped if the validation
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accuracy starts to decrease, as a sign of overﬁtting. For LSTM networks, dropout68
was included, set at 0.5 while training. This ensured that model parameters
generalized to the validation data and beyond. During training, data batches were
selected at random. Given the stochastic nature of the training procedure, it was
likely that two realizations of the same model would not lead to the same results,
since models end up in different local minima. To measure the effect of this, two
realizations were made of each model.
Apart from model realizations, we also investigated the effect of ensembling our
sleep stage classiﬁcation model. In general, ensemble models can yield higher
predictive performance than any single model by attacking a classiﬁcation or
regression problem from multiple angles. For our speciﬁc use case, this resolves
into forming a sleep stage prediction based on the predictions of all the models in
the given ensemble. We tested several ensembles containing various numbers
of model architectures and data encodings, as described in Supplementary Table 8.
Performance comparisons of generated CNN models. As stated, the inﬂuences
of many different factors were analyzed. These included: using octave or CC
encoding, short (5 s) or long (15 s) segment lengths, low or high complexity, with
or without LSTM, and using a single or two realizations of a model. To quantify the
effect of each, a 25-factorial experiment was designed. This led to 32 different
models (Supplementary Table 8). Comparison between models was done on a per-
epoch basis.
Hypnodensity as feature for the diagnosis of T1N. To quantify narcolepsy-like
behavior for a single recording i, features were generated based on a proto-feature
derived from k-combinations of S ¼ fW;REM;N1;N2;N3g. For the nth 5, 15
or 30 s segment in recording i, we take a single k-combination in the set of all
k-combinations, and calculate the proto-feature as the sum of the pair-wise pro-
ducts of the elements in the single k-combination, such that
ΦðiÞn Skð Þ ¼
X
ζ2½Sk 2
Y
s2ζ
p sjxðiÞn
 
; p 2 0; 1½ ; ð9Þ
where ΦðiÞn is the proto-feature for the nth segment in recording i, ζ 2 ½Sk2 is a 2-
tuple, or pair-wise combination, in the set of all pair-wise combinations in the k-
combination of S and s is a single element, or sleep stage, in ζ . For k ¼ 1; ¼ ; 5,
there exist 31 different Sk , e.g., {Wake, REM}, {N1, N2, N3} etc., as shown in
Supplementary Table 9. p sjxðiÞn
 
is the predicted probability of a 5, 15 or 30 s
epoch belonging to a certain class in S, given the data xðiÞn . For every value of k, 15
features based on the mean, derivative, entropy and cumulative sum were
extracted, as shown in Supplementary Table 10.
Additional features for T1N diagnosis. In addition to above, another set of
features reﬂecting abnormal sleep stage sequencing in T1N was investigated.
One set of such features was selected because they have been found to
differentiate T1N from other subjects in prior studies37,69–72. These include:
nocturnal sleep REM latency (REML)10, presence of a nightly SOREMP (REML
≤15 min)10, presence and number of SOREMPs during the night (SOREMPs
deﬁned as REM sleep occurring after at least 2.5 min of wake or stage 1) and
nocturnal sleep latency (a short sleep latency is common in narcolepsy)37. Other
features include a NREM Fragmentation index described in Christensen et al.37.
(N2 and N3 combined to represent unambiguous NREM and N1 and wake
combined to denote wake, NREM fragmentation deﬁned as 22 or more occurrences
where sustained N2/N3 (90 s) is broken by at least 1 min of N1/Wake), and the
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number of W/N1 hypnogram bouts as deﬁned by Christensen et al.37. (N1 and
wake combined to indicate wakefulness and a long period deﬁned as 3 min or
more). In this study we also explore: the cumulative wake/N1 duration for
wakefulness periods shorter than 15 min; cumulative REM duration following
wake/N1 periods longer than 2.5 min; and total nightly SOREMP duration deﬁned
as the sum of REM epochs following 2.5 minW/N1 periods.
Another set of 9 features reﬂecting hypnodensity sleep stage distribution was
also created as follows. As noted in Supplementary Figure 4, stages of sleep
accumulate, forming peaks. These peaks were then used to create 9 new features
based on the order of the peaks, expressing a type of transition (W to N2, W to
REM, REM to N3 etc.). If the height of the nth peak is denoted as φn, the transition
value τ is calculated as the geometric mean between successive peaks:
τn ¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃφn  φnþ1p : ð10Þ
Due to their likeness, W and N1 peaks were added to form a single type.
All transitions of a certain type were added together to form a single feature. A
lower limit of 10 was imposed on peaks to avoid spurious peaks. If two peaks
of the same type appeared in succession the values were combined into a single
peak.
Gaussian process models for narcolepsy diagnosis. To avoid overﬁtting, and at
the same time produce interpretable results, a RFE algorithm was employed, as
described in Guyon et al.42. Post screening, the most optimal features (n= 38) were
used in a GP classiﬁer as described below. GP classiﬁers are non-parametric
probabilistic models that produce robust non-linear decision boundaries using
kernels, and unlike many other classiﬁcation tools, provide an estimate of the
uncertainty. This is useful when combining estimates, but also when making a
diagnosis; if an estimate is particularly uncertain, a doctor may opt for more tests to
increase certainty before making a diagnosis. In a GP, a training dataset is used to
optimize a set of hyper-parameters, which specify the kernel function, the basis
function coefﬁcients, here a constant, noise variance, and to form the
underlying covariance and mean function from which inference about new cases
are made73. In this case, the kernel is the squared exponential: σ2f exp
 xx′j j2
2l2
h i
. Two
classes were established: narcolepsy type 1 and “other”, which contains every other
subject. These were labeled 1 and −1 respectively, placing all estimates in this
range. For more information on GP in general, see the textbook by Rasmussen
and Williams73, while more information on variational inference for scalable
GP classiﬁcation can be found in the paper by Hensman et al.74 and Matthews
et al.75.
HLA-DQB1*06:02 testing. HLA testing plays a role in T1N diagnosis, as 97% of
patients are DQB1*06:02 positive when the disease is deﬁned biochemically by low
CSF hypocretin-15 or by the presence of cataplexy and clear MSLT ﬁndings10. As
testing for HLA-DQB1*06:02 only requires a single blood test, models in which this
feature was included were also tested. The speciﬁc feature was implemented as a
binary-valued predictor, resulting in negative narcolepsy predictions for subjects
with a negative HLA test result.
High pretest probability sample. MSLTs are typically performed in patients with
daytime sleepiness that cannot be explained by OSA, insufﬁcient/disturbed sleep or
circadian disturbances. These patients have a higher pretest probability of having
T1N than random clinical patients. Patients are then diagnosed with type 1 or type
2 narcolepsy, idiopathic hypersomnia or subjective sleepiness based on MSLT
results, cataplexy symptoms and HLA results (if available). To test whether our
detector differentiates T1N from these other cases with unexplained sleepiness, we
conducted a post hoc analysis of the detector performance in these subjects
extracted from both the test and replication datasets.
Data availability
All the software is made available in GitHub at: https://github.com/stanford-stages/
stanford-stages. We asked all contributing co-authors whether we could make the
anonymized EDF available, together with age, sex and T1N diagnosis (Y/N). The
SSC10,32 (E.M.), the IS-RC31 (S.T.K., C.K., P.K.S.), the KHC (S.C.H.), the HIS (G.
P.), the DHS (P.J.), the FHC (Y.D.) and associated data are available at https://
stanfordmedicine.app.box.com/s/r9e92ygq0erf7hn5re6j51aaggf50jly. The AHC (B.
H.) and the CNC12 (F.H.) are available from the corresponding investigator on
reasonable request. The WSC32,33 data analyzed during the current study are not
publicly available due to speciﬁc language contained in informed consent docu-
ments limiting use of WSC human subjects’ data to speciﬁed institutionally
approved investigations. However, WSC can be made available from P.E.P. on
reasonable request and with relevant institutional review board(s) approval. The
JCTS43 and AASM ISR16 dataset are available from the corresponding institutions
on reasonable request.
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